Massachusetts
|
001-38787
|
83-1895370
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
Common Stock, no par value
|
CYCN
|
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
|
Item 5.07. |
Submission of Matters to a Vote of Security Holders.
|
For
|
Against
|
Abstain
|
||
23,981,513
|
132,953
|
2,616
|
Cyclerion Therapeutics, Inc.
|
|||
Dated: June 25, 2021
|
By:
|
/s/ Anjeza Gjino
|
|
Name:
|
Anjeza Gjino
|
||
Title:
|
Chief Financial Officer
|